1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-94.
2.
Sampogna F, Gisondi P, Melchi CF, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-9.
3.
Elewski B, Alexis AF, Lebwohl M, et al. Itch: an under-recognized problem in psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1465-76.
4.
Hrehorów E, Salomon J, Matusiak L, et al. Patients with psoriasis feel stigmatized. Acta Derm Venereol 2012; 92: 67-72.
5.
Lesner K, Reich A, Szepietowski JC, et al. Determinants of psychosocial health in psoriatic patients: a multinational study. Acta Derm Venereol 2017; 97: 1182-8.
6.
Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
7.
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
8.
Cheung HN, Chan YS, Hsiung NH. Validation of the 5-D itch scale in three ethnic groups and exploring optimal cutoff values using the itch numerical rating scale. Biomed Res Int 2021; 2021: 7640314.
9.
Reich A, Mędrek K, Szepietowski J. Four-item itch questionnaire-validation of questionnaire. Dermatol Rev 2012; 99: 600-4.
10.
Herrmann C. International experiences with the hospital anxiety and depression scale – a review of validation data and clinical results. J Psychosom Res 1997; 42: 17-41.
11.
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092-7.
12.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-13.
13.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
14.
Lu Y, Duller P, Van Der Valk PGM, Evers AWM. Helplessness as predictor of perceived stigmatization in patients with psoriasis and atopic dermatitis. Dermatol Psychosom 2003; 4: 146-50.
15.
Dimitrov D, Szepietowski JC. Instruments to assess stigmatization in dermatology. Postepy Hig Med Dosw 2017; 71: 901-5.
16.
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Investig Dermatol 2014; 134: 1542-51.
17.
Jalenques I, Bourlot F, Martinez E, et al. Prevalence and odds of anxiety disorders and anxiety symptoms in children and adults with psoriasis: systematic review and meta-analysis. Acta Derm Venereol 2022; 102: adv00769.
18.
Adesanya EI, Matthewman J, Schonmann Y, et al. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. Br J Dermatol 2023; 188: 460-70.
19.
Szepietowski JC, Krajewski PK, Pacan P. Psoriasis: an inflammatory skin disease affecting the mind. J Eur Acad Dermatol Venereol 2024; 38: 460-1.
20.
Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-57.
21.
Tabra SA, Abd Elghany SE, Amer RA, et al. Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin Rheumatol 2022; 41: 3391-9.
22.
Raber J, O’Shea RD, Bloom FE, Campbell IL. Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 1997; 17: 9473-80.
23.
Amatya B, Wennersten G, Nordlind K. Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 2008; 22: 822-6.
24.
Szepietowski JC, Reich A, Wiśnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 2002; 10: 221-6.
25.
Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-73.
26.
Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes 2009; 7: 62.
27.
Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol 2015; 29: 1114-20.
28.
Kimball AB, Edson-Heredia E, Zhu B, et al. Understanding the relationship between pruritus severity and work productivity in patients with moderate-to-severe psoriasis: sleep problems are a mediating factor. J Drugs Dermatol 2016; 15: 183-8.
29.
Zamirska A, Reich A, Berny-Moreno J, et al. Vulvar pruritus and burning sensation in women with psoriasis. Acta Derm Venereol 2008; 88: 132-5.
30.
Reich A, Hrehorow E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010; 90: 257-63.
31.
Verhoeven EWM, Kraaimaat FW, van de Kerkhof PCM, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156: 1346-9.
32.
Gupta MA, Gupta AK, Kirkby S, et al. Pruritus in psoriasis: a prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988; 124: 1052-7.
